Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mikoferon
- Development stage
- Unknown
- Lead developer
- Firn-M
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Mikoferon is a topical combination pharmaceutical developed by the Russian company Firn M for the treatment of fungal skin infections, such as dermatomycosis. It is formulated as an ointment containing recombinant human interferon alfa-2b and the antifungal agent terbinafine. The interferon component acts as an agonist at the interferon alpha/beta receptor (IFNAR), triggering signaling pathways that enhance local innate and adaptive immune responses to help the body combat the infection. Terbinafine, a small molecule allylamine, provides direct antifungal activity by inhibiting the enzyme squalene epoxidase. This inhibition disrupts the biosynthesis of ergosterol, a critical component of fungal cell membranes, leading to fungal cell death. By combining immunomodulatory and fungicidal actions, Mikoferon aims to effectively clear cutaneous fungal pathogens while supporting the local immune environment to prevent recurrence.
- Brand names
- MikoferonМикоферон
- Other names
- Mikoferon-Firn M
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)SQLE (Squalene monooxygenase)
Beyond the preview
Go deeper on Mikoferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mikoferon.